Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 2 Months to 59 Months

AI-enabled digital stethoscope to guide antibiotic use in young children with pneumonia

Official title: The BLAAAST Trial: Bangladesh Lung Auscultation AI for Antibiotic Stewardship Randomized Controlled Trial

Run by Johns Hopkins University · NCT07362433 · Data updated 2026-11-12

This trial tests whether using an AI-assisted digital stethoscope to guide antibiotic decisions in children with suspected non-severe pneumonia is no worse than standard care at treating them with antibiotics.

Quick facts

PhasePhase 4
Study typeInterventional
Ages2 Months to 59 Months
SexAll
Enrollment2500 (estimated)
SponsorJohns Hopkins University
Academic / other
Locations1 site (Sylhet)
StatusRecruiting
StartedJune 2, 2026
Main results expectedJune 30, 2029
Study endsJune 30, 2029
Registry record updatedJune 8, 2026
Trial IDNCT07362433 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 2 to 59 months with non-severe pneumonia meeting IMCI criteria in the trial catchment areas.

Probably not a fit

Children whose lung sounds or clinical presentation do not align with the AI algorithm’s classification may not benefit from the AI-guided approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 trial in rural Bangladesh evaluates whether an AI-enabled digital stethoscope can help clinicians decide when antibiotics are needed for children with non-severe pneumonia, potentially reducing unnecessary antibiotic use. Children aged 2 to 59 months with symptoms up to 14 days and meeting IMCI non-severe pneumonia criteria are enrolled, have lung sounds recorded, and are randomized to an AI-guided antibiotic plan or standard care. In the intervention arm, lung-sound analysis determines antibiotic treatment, while all control participants receive standard antibiotic therapy per IMCI guidelines. The primary aim is to determine non-inferiority in treatment failure between the AI-guided approach and standard care. The study uses encrypted data transfer, randomized allocation after recording, and a 5-day antibiotic course when indicated by IMCI guidance.

Why it matters

Potential benefit: If successful, this approach could reduce unnecessary antibiotic use and help preserve antibiotic effectiveness in resource-limited settings.

How similar studies have gone: Previous work in automated auscultation and AI-assisted diagnosis has shown promise but this exact non-inferiority design in a rural, pediatric population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 2 to 59 months of age (60 days to 59 months 29 days),
* illness duration 14 days or less,
* meeting non-severe pneumonia criteria, and
* from the trial catchment areas.

Exclusion Criteria:

* prior participation,
* age \<2 months or \>59 months,
* illness duration \>14 days,
* not meeting IMCI-defined non-severe pneumonia criteria,
* oxygen saturation (SpO2) \<90%,
* moderate or severe malnutrition,
* known chronic disease,
* history of prematurity,
* one or more high risk clinical signs (any WHO-defined clinical danger sign and/or WHO-defined emergency sign),
* known antibiotic exposure in the past 1 week,
* non-respiratory illness requiring systemic antibiotic treatment according to IMCI guidelines.

Where it's running

  • Projahnnmo Research Foundation
    Sylhet, Bangladesh
    Recruiting

Study contacts

  • Principal investigator: Eric McCollum, MD, MPH — Johns Hopkins University
  • Study coordinator: Eric D McCollum, MD, MPH
  • Email: emccoll3@jhmi.edu
  • Phone: 410-955-2035

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.